Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised …
…, G Niegisch, PJ Goebell, M Boegemann… - The Lancet …, 2021 - thelancet.com
Background PD-1 and PD-L1 inhibitors are active in metastatic urothelial carcinoma, but
positive randomised data supporting their use as a first-line treatment are lacking. In this study …
positive randomised data supporting their use as a first-line treatment are lacking. In this study …
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a …
Background Abiraterone acetate plus prednisone or prednisolone improves progression-free
survival and overall survival in patients with metastatic castration-resistant prostate cancer. …
survival and overall survival in patients with metastatic castration-resistant prostate cancer. …
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
AJ Schrader, M Boegemann, CH Ohlmann… - European urology, 2014 - Elsevier
Background Abiraterone, an androgen synthesis inhibitor, has been successfully used in the
treatment of castration-resistant prostate cancer (CRPC) for 2 yr. Enzalutamide is a second-…
treatment of castration-resistant prostate cancer (CRPC) for 2 yr. Enzalutamide is a second-…
Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant …
…, M Luedeke, K Steinestel, M Boegemann… - European urology, 2017 - Elsevier
The androgen receptor splice variant AR-V7 has recently been discussed as a predictive
biomarker for nonresponse to next-generation androgen deprivation therapy (ADT) in patients …
biomarker for nonresponse to next-generation androgen deprivation therapy (ADT) in patients …
[HTML][HTML] Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy
…, J Kleesiek, M Weckesser, M Boegemann… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-specific
membrane antigen (PSMA) in vivo, which is the target molecule of 177 Lu-PSMA-617 (Lu-PSMA…
membrane antigen (PSMA) in vivo, which is the target molecule of 177 Lu-PSMA-617 (Lu-PSMA…
[HTML][HTML] PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric …
…, M Schäfers, M Weckesser, M Boegemann… - European Journal of …, 2021 - Springer
Introduction [ 177 Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment
option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy …
option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy …
Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis
…, M Retz, AS Merseburger, CA Von Klot, M Boegemann… - European urology, 2015 - Elsevier
… Martin Boegemann received lecture fees and honoraria from Astellas Pharma GmbH,
Janssen-Cilag GmbH, Pfizer GmbH, Bayer AG, Teva GmbH, and GlaxoSmithKline GmbH & Co. KG…
Janssen-Cilag GmbH, Pfizer GmbH, Bayer AG, Teva GmbH, and GlaxoSmithKline GmbH & Co. KG…
Efficacy and safety of autologous dendritic cell–based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate …
…, B Keck, C Wuelfing, A Winter, M Boegemann… - JAMA …, 2022 - jamanetwork.com
Importance DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune
response against prostate cancer. Objective To evaluate the efficacy and safety of DCVAC/…
response against prostate cancer. Objective To evaluate the efficacy and safety of DCVAC/…
The percentage of prostate‐specific antigen (PSA) isoform [–2] pro PSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate …
M Boegemann, C Stephan, H Cammann… - BJU …, 2016 - Wiley Online Library
Objectives To prospectively test the diagnostic accuracy of the percentage of prostate specific
antigen ( PSA ) isoform [–2]pro PSA (%p2 PSA ) and the Prostate Health Index ( PHI ), and …
antigen ( PSA ) isoform [–2]pro PSA (%p2 PSA ) and the Prostate Health Index ( PHI ), and …
[HTML][HTML] Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617
…, M Weckesser, K Schlack, M Boegemann… - Theranostics, 2019 - ncbi.nlm.nih.gov
The purpose of this study was to identify previous treatments and biomarker profile features
that prognosticate overall survival (OS) in patients with mCRPC receiving 177 Lu-PSMA-617. …
that prognosticate overall survival (OS) in patients with mCRPC receiving 177 Lu-PSMA-617. …